Roche and Foundation Medicine - Genetic Diagnostics Europe Solutions/Service Company
healthcaretechoutlook
Home
>> Genetic Diagnostics Europe >> Vendors>> Roche and Foundation Medicine

Roche and Foundation Medicine: Transforming Cancer Care with Comprehensive Genomic Profiling

Follow Roche and Foundation Medicine on :

Vera Grossmann, Vice President of International Operations and Managing Director, Foundation Medicine, GmbH, based in Germany; Robert Loberg, Vice President and Lifecycle leader for the Oncology & Genetics team at Roche Diagnostics, Roche and Foundation MedicineVera Grossmann, Vice President of International Operations and Managing Director, Foundation Medicine, GmbH, based in Germany; Robert Loberg, Vice President and Lifecycle leader for the Oncology & Genetics team at Roche Diagnostics, Roche and Foundation Medicine
Even after half a century’s worth of research and development (R&D) in cancer diagnosis and treatment, it remains a leading cause of death worldwide. Cancer is unique to each individual due to the specific genomic alterations in the tumor’s DNA. As a result, physicians working to determine effective personalized care strategies for their patients have to sift through vast datasets—often from multiple genomic test reports that look at limited numbers of mutations within a subset of genes. When combined with the ever-evolving nature of cancer genomic profiling, this can pose hurdles in examining the vital information required to deliver impactful diagnosis and treatment.

Foundation Medicine, Inc., a wholly owned subsidiary of Roche, mitigates this challenge with its suite of comprehensive genomic profiling (CGP) assays that can identify molecular alterations in a patient’s cancer in one comprehensive panel and match them with an overview of best-suited targeted therapies, immunotherapies or clinical trials via a detailed results report. By determining options of a treatment path tailored to the unique genomic profile of a person’s tumor, the technology can help patients avoid unnecessary treatments and unpleasant side effects, subsequently supporting healthcare systems to be more sustainable in the long term. The company’s CGP tests can evaluate blood and tissue samples with a single biopsy to assess more than 300 genes known to be associated with cancer behavior and growth.

“Our high-quality CGP assays provide physicians with insights into the unique biology of each patient to support clinical decision-making, and drive faster development of new life-saving cancer treatments,” says Vera Grossmann, Vice President of International Operations and Managing Director, Foundation Medicine, GmbH, based in Germany. In addition, with emerging blood-based CGP tests, physicians will be able to monitor the progress of a patient’s cancer over time using blood samples to identify any possible signs of treatment resistance. They can then develop a new treatment plan accordingly, and patients may avoid multiple tissue biopsy procedures as the cancer progresses.

Foundation Medicine’s mission is to transform cancer care by consolidating all the information needed to make a data-driven clinical decision. In 2018, the company was acquired by the Roche Group, combining Foundation Medicine’s world renowned next-generation sequencing (NGS) offerings with Roche’s cancer R&D expertise.

Together, Foundation Medicine and Roche have developed a research use-only offering, called the AVENIO Tumor Tissue CGP kit, which provides an end-to-end workflow from DNA extraction and library preparation to generation of variant results by the FoundationOne® Analysis Platform.

The Kit uses a gene panel designed to match the FoundationOne® CDx panel across four main classes of genomic alterations and genomic signatures known to cause and drive cancer.

The AVENIO Tumor Tissue CGP Kit is designed to allow labs to conduct oncology research with CGP in-house, expanding personalized cancer research and supporting researchers in navigating the complex landscape of cancer. All of these assays are backed by the company’s unique knowledge base, FoundationCore® one of the largest databases of real-world anonymous CGP results in oncology, which evaluates the genomic landscape across cancer types to better understand tumor biology, molecular biomarkers, and appropriate treatments, enabling researchers and biopharma companies to develop new therapies and design better clinical trials, and advance precision medicine.

Combining genomic data with patient clinical history data—for example past and current illnesses and the efficacy of treatments over time—can provide additional pieces to the complex puzzle. In partnership with Flatiron Health, Roche and Foundation Medicine have completed an ambitious project to combine a subset of their data into the first-of-its-kind clinico-genomic database. The FMI-Flatiron Health database recently reached more than 100,000 patients and has enabled the company and its partners to publish more than 100 publications focused on precision oncology.

“Our mission going forward is to transform cancer care by blending our diagnostics prowess with Foundation Medicine’s decade-long CGP expertise, enriched with powerful genomic data insights, to make impactful and timely clinical decisions possible for physicians and diagnosticians worldwide, in turn improving outcomes for patients,” states Robert Loberg, Vice President and Lifecycle leader for the Oncology & Genetics team at Roche Diagnostics.


Our high-quality CGP assays provide physicians with insights into the unique biology of each patient to support clinical decision-making, and drive faster development of new life-saving cancer treatments


In a world where the state-of-the-art evaluation of cancer patients is predominantly focused within large healthcare systems and research facilities, Roche and Foundation Medicine’s combination of expertise allows them to offer a portfolio of solutions, including decentralized testing options. By doing this, Foundation Medicine aims to support physicians and researchers to gain a deeper understanding of the disease and ultimately reshape the healthcare system, redefine the way each patient with cancer is treated, make cancer a more manageable disease (particularly in the advanced setting), and enable many more patients with cancer to lead a long, fulfilling life that is not dominated and defined by their disease.
Share this Article:
Top 10 Genetic Diagnostics Solutions Companies In Europe - 2022
Roche and Foundation Medicine

Company
Roche and Foundation Medicine

Headquarters
Cambridge, Massachusetts

Management
Vera Grossmann, Vice President of International Operations and Managing Director, Foundation Medicine, GmbH, based in Germany; Robert Loberg, Vice President and Lifecycle leader for the Oncology & Genetics team at Roche Diagnostics , Roche and Foundation Medicine

Description
A molecular information company dedicated to a transformation in cancer care in which a deep understanding informs treatment of the genomic changes that contribute to each patient’s unique cancer